Milestone Scientific (NYSEAMERICAN:MLSS)‘s stock had its “buy” rating reiterated by analysts at Maxim Group in a note issued to investors on Friday, AnalystRatings.com reports. They currently have a $2.00 target price on the medical instruments supplier’s stock. Maxim Group’s price target indicates a potential upside of 72.41% from the stock’s current price.
Milestone Scientific stock opened at $1.16 on Friday. Milestone Scientific has a 1 year low of $0.26 and a 1 year high of $1.41.
Milestone Scientific (NYSEAMERICAN:MLSS) last released its quarterly earnings data on Wednesday, August 14th. The medical instruments supplier reported ($0.02) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.02). The company had revenue of $2.26 million for the quarter.
About Milestone Scientific
Milestone Scientific, Inc develops computer-controlled anesthetic delivery devices for the medical and dental markets in the United States and internationally. The company operates through dental and medical segments. Its products include CompuDent System used to control the flow rate of the anesthesia during the injection that allows virtually painless injections for various dental procedures, including routine fillings, implants, root canals, and crowns; and CompuFlo, a computer-controlled drug delivery system for the painless delivery of drugs, anesthetics, and other medicaments, as well as for the aspiration of bodily fluids or previously injected substances.
Further Reading: Hang Seng Index (HSI)
Receive News & Ratings for Milestone Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Scientific and related companies with MarketBeat.com's FREE daily email newsletter.